|Dr. Joseph K. Belanoff M.D.||Co-Founder, President, CEO & Director||1.82M||19.31M||1957|
|Mr. Atabak Mokari||CFO & Treasurer||760.75k||N/A||1977|
|Dr. Hazel Hunt Ph.D.||Chief Scientific Officer||895.16k||1.75M||1960|
|Mr. Sean Maduck||President of Corcept Endocrinology||823.42k||3.37M||1977|
|Mr. Gary Charles Robb||Chief Business Officer & Secretary||963k||4.82M||1963|
|Mr. Joseph Douglas Lyon||Chief Accounting Officer||N/A||N/A||1979|
|Ms. Amy Flood||Chief Human Resources & Communications Officer||N/A||N/A||N/A|
|Dr. William Guyer Pharm.D.||Chief Development Officer||N/A||N/A||1968|
|Ms. Monica Tellado||President of Emerging Markets||N/A||N/A||1973|
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Corcept Therapeutics Incorporated’s ISS governance QualityScore as of 28 November 2023 is 6. The pillar scores are Audit: 4; Board: 4; Shareholder rights: 6; Compensation: 8.